Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesa Laboratories SEC filings document the company's life sciences tools and critical quality control business, its Nasdaq-listed common stock and formal disclosures around operating results, governance and capital structure. Form 8-K reports furnish quarterly financial releases, record annual meeting voting outcomes and report executive succession, director changes and related compensation arrangements.
Other filings and exhibits describe the company's credit facility borrowings, convertible note settlement funding, independent auditor ratification, board committee structure and proxy compensation disclosures. These records frame Mesa's disclosure obligations across its four operating divisions and its financing, shareholder-vote and leadership-transition matters.
On August 5, 2025, Mesa Laboratories, Inc. (Ticker: MLAB) filed a Form 8-K reporting that it issued a press release relating to its results for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the Form 8-K.
The Form 8-K states that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act and shall not be incorporated by reference into registration statements under the Securities Act. The filing also lists Exhibit 104 (Cover Page Interactive Data File). The report is signed by Gary M. Owens, President and Chief Executive Officer, dated August 5, 2025, and includes the registrant address and Nasdaq listing (symbol MLAB).
Mesa Laboratories (NASDAQ:MLAB) CFO John Sakys reported multiple transactions on June 21, 2025. The transactions involved the vesting of 1,036 Restricted Stock Units (RSUs) and subsequent sale of 454 shares for tax withholding purposes at $95.82 per share. Following these transactions, Sakys directly owns 15,044 shares and indirectly holds 100 shares as custodian for his children.
Mesa Laboratories (NASDAQ:MLAB) reported insider trading activity through a Form 4 filing for SVP Operations Brian David Archbold. The transactions occurred on June 21, 2025, involving restricted stock units (RSUs). Archbold acquired 844 shares at $95.82 per share through RSU conversion and subsequently disposed of 385 shares at the same price, likely for tax withholding purposes. Following these transactions, Archbold holds 2,407 shares directly.
Form 4 filing – Mesa Laboratories Inc. (MLAB)
President & CEO Gary M. Owens reported two transactions dated 06/21/2025: (1) the conversion of 3,301 Restricted Stock Units (Code “M”) into common stock at a referenced price of $95.82 per share, and (2) the withholding of 1,445 shares for tax purposes (Code “F”) at the same price. Following these transactions, Owens’ direct ownership rose from an implied 50,721 shares to 52,577 shares, a net increase of 1,856 shares. The RSUs originated from a grant that vests one-third annually (2024-2026). No open-market purchases or sales were disclosed; all activity relates to equity compensation.
The filing is routine, indicating continued equity alignment but limited new cash investment by the insider.
Mesa Laboratories Inc. (MLAB) – Form 4 insider transaction dated 06/18/2025
Senior Vice-President of Operations Brian D. Archbold reported the automatic conversion of 2,556 restricted stock units (RSUs) into common shares (Transaction Code M) at a reference price of $92.99 per share. To cover tax obligations, he simultaneously disposed of 1,166 shares via a tax-withholding transaction (Code F) at the same price.
Post-transaction direct holdings changed as follows:
- Common stock: 1,948 shares now held directly (down from 3,114 immediately after the RSU conversion).
- Unvested/remaining RSUs: 4,960 units retained, scheduled to vest one-third on 18 June 2025 and on each of the next two anniversaries.
The activity reflects routine equity compensation vesting rather than an open-market purchase or sale; no cash was exchanged for the share acquisition portion.
Mesa Laboratories, Inc. (MLAB) – Form 4 insider transaction filed 06/20/2025
CFO John Sakys reported activity dated 06/18/2025 involving the exercise and settlement of restricted stock units (RSUs) and related tax withholding.
- RSU exercise (Code M): 2,840 common shares were issued upon vesting of previously granted RSUs. Each RSU converts 1-for-1 into common stock.
- Tax withholding (Code F): 1,243 of the newly issued shares were automatically withheld at a reference price of $92.99 to satisfy tax obligations.
After the transactions, Sakys’ direct beneficial ownership changed from 12,865 shares to 14,462 shares, a net increase of 1,597 shares (≈12.4%).
The RSU award vests in three equal annual installments beginning 06/18/2025, providing future potential share deliveries on the next two anniversary dates.
No derivative positions remain other than 5,511 unvested RSUs outstanding.
Because the share acquisition arose from planned equity compensation rather than open-market buying, the filing signals routine ownership growth rather than an active market purchase, though the net increase modestly aligns the CFO’s incentives with shareholders.